NCT02699710View on ClinicalTrials.gov

Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 3, 2015

Primary Completion Date

May 26, 2016

Study Completion Date

May 26, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

Folic Acid

Folic acid will be administered orally as tablet at a single dose of 5 mg.

DRUG

GDC-0853

GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.

DRUG

Methotrexate

Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.

DRUG

Rabeprazole

Rabeprazole will be administered orally as tablet at a dose of 20 mg.

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Clinical Research Unit, Nottingham

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects | Biotech Hunter | Biotech Hunter